Abstract：Objective To compare the efficacy of Decitabine and Azacitidine in the treatment of high-risk myelodysplastic syndrome.Methods A total of 60 patients with high-risk myelodysplastic syndrome admitted to Yichun People′s Hospital from January 2018 to January 2020 were selected as the research subjects.According to the random number table method, they were divided into Decitabine group and Azacitidine group, with 30 cases in each group.In the Decitabine group, Decitabine was used, and in the Azacitidine group, Azacitidine was adopted.The clinical efficacy and the occurrence of side effect were compared between the two groups after six courses of treatment.Results The overall response rate (ORR) of the Decitabine group after six courses of treatment was higher than that of the Azacitidine group, and the difference was statistically significant (P＜0.05).In the Decitabine group, the incidence of bone marrow suppression, reduction of neutrophils, thrombocytes, and erythrocytes was superior to that in the Azacitidine group, and the difference was statistically significant (P＜0.05).Conclusion Decitabine is better than Azacitidine in the treatment of high-risk myelodysplastic syndrome, but it will increase the risk of toxic and side effect, which should be with caution on drug selection.
卢玉华； 杨新平； 敖志文； 李明. 地西他滨与阿扎胞苷治疗高危骨髓增生异常综合征的疗效比较研究[J]. 中国当代医药, 2021, 28(10): 180-182转186.
LU Yu-hua； YANG Xin-ping； AO Zhi-wen； LI Ming. Comparative study of the efficacy of Decitabine and Azacitidine in the treatment of high-risk myelodysplastic syndrome. 中国当代医药, 2021, 28(10): 180-182转186.
Chinese Society of Hematology，Chinese Medical Association.骨髓增生异常综合征中国诊断与治疗指南（2019年版）[J].中华血液学杂志，2019，40（2）：89-97.
[6]
沈悌，赵永强.血液病诊断及疗效标准（第4 版）[M].北京：科学出版社，2020：75-79.
[7]
Chung AE，Shoenbill K，Mitchell SA，et al.Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute′s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events（PRO-CTCAE）[J].J Am Med Inform Assoc，2019，26（4）：276-285.
京公网安备 11010502046607号